Amgen Q1 FY26: where the revenue came from and where it went
The whole income statement of Amgen for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jan 1 – Mar 31, 2026
- Reported
- May 1, 2026
Revenue$8.62B
+6% year over year
Gross profit$5.87B
68% margin
Operating profit$2.67B
31% margin
Net profit$1.82B
21% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 8.62 | 100% | +6% |
| Other revenue | 3.59 | 42% | |
| Other products | 1.53 | 18% | |
| Repatha (evolocumab) | 0.88 | 10% | +34% |
| Prolia | 0.73 | 8% | −34% |
| Evenity | 0.56 | 6% | +27% |
| Tepezza | 0.49 | 6% | |
| Otezla | 0.43 | 5% | −1% |
| Blincyto | 0.42 | 5% | |
| Cost of revenue | −2.74 | 32% | |
| Gross profit | 5.87 | 68% margin | +5pp |
| SG&A | −1.60 | 18% | −2pp |
| Other | −1.61 | 19% | |
| Operating profit | 2.67 | 31% margin | +16pp |
| Interest & other costs | −0.58 | ||
| Tax | −0.27 | ||
| Net profit | 1.82 | 21% margin | +0pp |
107 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest